Metabolic syndrome as cardiovascular risk factor in childhood cancer survivors

• Published in: Critical reviews in oncology/hematology Vol. 133; pp. 129 - 141
• Main Authors: Pluimakers, V.G., van Waas, M., Neggers, S.J.C.M.M., van den Heuvel-Eibrink, M.M.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.01.2019
• Subjects: Adult; Age of Onset; Cancer Survivors - statistics & numerical data; Cardiovascular disease; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - etiology; Child; Childhood cancer survivor; Diabetes mellitus; Dyslipidemia; Humans; Hypertension; Incidence; Insulin resistance; Metabolic syndrome; Metabolic Syndrome - complications; Metabolic Syndrome - epidemiology; Neoplasms - complications; Neoplasms - epidemiology; Obesity; Risk Factors; Hypertension; Obesity; Childhood cancer survivor; Diabetes mellitus; Dyslipidemia; Cardiovascular disease; Insulin resistance; Metabolic syndrome
• ISSN: 1040-8428; 1879-0461
• DOI: 10.1016/j.critrevonc.2018.10.010

[Display omitted] Over the past decades, survival rates of childhood cancer have increased considerably from 5 to 30% in the early seventies to current rates exceeding 80%. This is due to the development of effective chemotherapy, surgery, radiotherapy and stem cell transplantation, combined with an optimized stratification of therapy and better supportive care regimens. As a consequence, active surveillance strategies of late sequelae have been developed to improve the quality of survival. Several epidemiological studies have reported an increased incidence of (components of) metabolic syndrome (MetS) and cardiovascular disease in childhood cancer survivors (CCS). Growth hormone deficiency (GHD) after cranial radiotherapy (CRT) has been previously described as an important cause of MetS. New insights suggest a role for abdominal radiotherapy as a determinant for MetS as well. The role of other risk factors, such as specific chemotherapeutic agents, steroids, gonadal impairment, thyroid morbidity and genetics, warrants further investigation. This knowledge is important to define subgroups of CCS that are at risk to develop (subclinical) MetS features. These survivors might benefit from standard surveillance and early interventions, for example lifestyle and diet advice and medical treatment, thereby preventing the development of cardiovascular disease.